|
Match
|
Document |
Document Title |
|
|
7550453 |
2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
The invention relates particularly to 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof as a medicament, particularly as anti-cancer agents.
|
|
|
7390798 |
Carboxamide spirolactam CGRP receptor antagonists
The present invention is directed to compounds of Formula I: I (where variables A 1 , A 2 , B, J, K, m, n, R 4 , R 5a , R 5b and R 5c are as defined herein) useful as antagonists of CGRP...
|
|
|
7288278 |
Process for preparing vegetable oil fractions rich in non-tocolic, high-melting, unsaponifiable matter
A vegetable oil fraction rich in non-tocolic, high-melting, unsaponifiable matter is prepared by the following steps: A vegetable oil having a slip melting point of not more thatn 30° C. and a...
|
|
|
7109161 |
Preserved pharmaceutical formulations
The present invention is directed to the use of benzethonium chloride, alone or in combination with phenoxyethanol or phenyl ethyl alcohol, to provide anti-microbial activity in pharmaceutical...
|
|
|
7101909 |
Calcium channel drugs and uses
Novel multibinding compounds are disclosed. The compounds of this invention comprise 2–10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a...
|
|
|
7053081 |
Cyclic malonamides as inhibitors of A-β protein production
This invention relates to novel cyclic malonamides having the formula (I):
to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of...
|
|
|
7049308 |
C-nitroso compounds and use thereof
A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon,...
|
|
|
7030110 |
Cyclic oxyguanidine pyrazinones as protease inhibitors
Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I:
wherein R 3 , R 4 , R 5 , W, and A are as set forth in the specification, as well as hydrates,...
|
|
|
7022693 |
Treatment of lipodystrophy
An inhibitor of the renin-angiotensin system is useful for the treatment or prevention of the lipodystrophy syndrome, e.g. in AIDS patients also receiving anti-retroviral therapy.
|
|
|
6977252 |
Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs
The present invention relates to use of compounds represented by the following general formula [1] or salts or prodrugs thereof:
[where R 1 represents hydrogen atom or lower alkoxy group; R 2 ...
|
|
|
6924277 |
Cyclized benzamide neurokinin antagonists for use in therapy
Compounds having the general formula
wherein R 1a , R 1b , R 1c , X 1 , X 2 , R 2 , R 3 , R 4 , R 5 , R 6 , n, Y and Z are as defined in the specification, methods of using such compounds for...
|
|
|
6864250 |
N-acylated lipophilic amino acid derivatives
Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group...
|
|
|
6716835 |
Use of diltiazem for treating retinal pathologies
The invention concerns the use of a calcium channel blocker compound and/or cyclic GMP-dependent channels, namely diltiazem, for treating retinal pathologies, and more particularly retinal diseases...
|
|
|
6624157 |
Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formulas and their enantiomers, diastereomers, and their...
|
|
|
6610682 |
Pharmaceutical compositions and methods for the treatment of arteriosclerosis
A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme...
|
|
|
6602865 |
Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
Pyridazino(4,5-b)(1,5)oxazepinone, thiazepinone and diazepinone compounds of formula(I) and their tautomers and the acid-addition salts of all these compounds show memory-enhancing and...
|
|
|
6544978 |
Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions...
|
|
|
6541466 |
Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions...
|
|
|
6514963 |
Methods for the inhibition of egg production in trematodes
The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective...
|
|
|
6503897 |
Antibacterial agents
Compounds of formula (I) are antibacterial agents wherein: R 3 and R 4 , taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated...
|
|
|
6337325 |
Combined preparation for the therapy of immune diseases
A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca 2+ content, is suitable...
|
|
|
6319915 |
Benzazepine derivatives as inhibitors of hyperproliferation diseases
A method of treating hyperproliferation diseases in mammals in need of such treatment which method includes administering to said mammal a therapeutically effective amount of a compound of the...
|
|
|
6156746 |
1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formula ##STR1## and their enantiomers, diastereomers, and their...
|
|
|
5990103 |
Combination preparation for use in immunological diseases
A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca 2 + content, is suitable...
|
|
|
5968925 |
Process for continuous sintering of granules
The invention relates to a process for continuous sintering of granules for the preparation of pellets, in particular medicament formulations in tablet form.
|
|
|
5929122 |
Combination preparation containing tramadol and a calcium channel antagonist
A pharmaceutical combination preparation, particularly for the treatment of pain, which contains a combination of the pain killer tramadol with at least one calcium channel antagonist, and a method...
|
|
|
5902609 |
Composition for the control of wound scar production
This invention pertains to a composition for controlling wound scar production containing a calcium antagonist and a protein synthesis inhibitor. The method can be used to minimize wound scars,...
|
|
|
5891845 |
Drug delivery systems utilizing liquid crystal structures
Vitamin E TPGS/drug compositions and methods are provided which obviate the need for surfactants or non-evaporated co-solvents because the active drug component is dissolved directly into Vitamin E...
|
|
|
5885979 |
N-containing condensed heterocyclic compounds, their production, and their uses
N-containing, condensed heterocyclic compounds and salts thereof are disclosed which are useful for inhibiting squalene synthetase and fungal growth, and which are useful for treating or preventing...
|
|
|
5854233 |
Method of treating liver disease and like indications with vasodilating agents
Liver diseases, such as cirrhosis of the liver, toxic and medicamentary liver damage, a liver-parenchymic disorder or hepatitis, are treated by administering to a human or animal subject in need...
|
|
|
5795897 |
Oxohexyl methylxanthine compounds
There is disclosed a pharmaceutical composition comprising 1-(5-oxohexyl)-3-methylxanthine in admixture with a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is...
|
|
|
5786344 |
Camptothecin drug combinations and methods with reduced side effects
This invention provides methods and combination formulations and kits to reduce the toxicity of camptothecin drugs, such as irinotecan (CPT-11). Disclosed are therapeutics and treatment methods...
|
|
|
5698549 |
Method of treating hyperactive voiding with calcium channel blockers
The instant invention discloses a method of treating hyperactive voiding associated with excessive nerve growth factor production and nerve growth in patients by administering a Ca + + channel...
|
|
|
5637582 |
Peripheral circulation improving agent
There is disclosed (-)-cis-1,5-benzothiazepine represented by the following formula or pharmaceutically acceptable salt thereof: ##STR1## wherein R 1 represents lower alkyl or lower alkoxy; R 2 ...
|
|
|
5618808 |
Benzothiazepine and benzoxazepine derivatives as cholecystokinin receptor antagonists
The present invention relates to novel substituted benzothiazepines and benzoxazepines of the formula ##STR1## wherein R 1 , R 2 , R 7 , R 8 , R 9 and X are as defined below, and to novel...
|
|
|
5610153 |
Benzazepinone derivatives
The invention relates to substituted 3-amino-1-arylalkyl-benzazepin-2-ones of the general formula ##STR1## wherein Ar is aryl; X is --O-- or --S(O) n -- and n is 0, 1 or 2; X 1 is C 1 -C 2...
|
|
|
5580867 |
Myocardial protection during ischemia and reperfusion
Myocardial protection is achieved by administering to a patient an effective amount of a benzothiazepine derivative. The benzothiazepine derivatives have the following general chemical formula:...
|
|
|
5571807 |
1,5 benzothiazepinone dervatives their preparation and pharmaceutical use
This invention relates to diltiazem analogs having the formula: ##STR1## where the substituents are defined in the specification. These compounds are useful in treating cardiovascular problems. The...
|
|
|
5569678 |
Control of wound scar production
This invention pertains to a method for controlling wound scar production by administering a calcium antagonist, alone or in a combination with or followed by a steroid, to the wound site. The...
|
|
|
5552162 |
Method for improvement of scar size and appearance
A method for improving the size and appearance of a scar associated with a fibromatosis, a keloid, or a hypertrophic wound healing disorder comprises stimulating collagenase activity in the scar....
|
|
|
5492904 |
Composition of angiotensin-II receptor antagonists and calcium channel blockers
Novel pharmaceutical compositions containing a combination of an angiotensin-II antagonist and a calcium channel blocker such as 2-butyl-4...
|
|
|
RE35095 |
Benzothiazepine anti-seizure method
Seizures are ameliorated with certain benzothiazepines.
|
|
|
5462936 |
Benzothiazepine derivatives
A compound of the formula: ##STR1## wherein X is N--A--R 1 or C(R 1 )R 2 ; A is a single bond, polymethylerie or --CO--; R 1 and R 2 are each hydrogen, C 1 -6 alkyl, C 3 -7 cycloalkyl,...
|
|
|
5387581 |
Pharmaceutical composition of aspirin and a benzothiazepine for inhibiting platelet aggregation
There is disclosed a pharmaceutical composition for inhibiting the platelet aggregation comprising acetylsalicyclic acid or a pharmaceutically acceptable salt thereof and a 1,5-benzothiazepine...
|
|
|
5382577 |
Pharmaceutical composition for inhibiting platelet aggregation
There is disclosed a pharmaceutical composition for inhibiting platelet aggregation comprising 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt...
|
|
|
5240922 |
Fertility enhancement
The present invention relates to a method of enhancing implantation of an embryo within the uterus of a female mammal. The method comprises administering an amount of a PAF antagonist, effective to...
|
|
|
5202130 |
Suppression of eczematous dermatitis by calcium transport inhibition
Treatment of an animal with calcium flux inhibitors results in a decrease in the number of epidermal Langerhans cells and a simultaneous decrease in the ability to respond to contact sensitizing...
|
|
|
H001139 |
Combination of a calcium channel blocker and thromboxane A.sub.2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination
A method is provided for treating ischemia in a mammalian species by administering a combination of a calcium channel blocker such as diltiazem, SQ 31,765 or SQ 32,324 and a thromoboxane A 2 ...
|
|
|
5162315 |
Penetration enhancers
Pharmaceutical compositions for enhancing absorption of a topically administered formulation through dermal or mucosal membrane, for local or systemic application, comprising one or more agents of...
|
|
|
5134139 |
1,5-benzothiazepine derivatives and preparation thereof
Novel 1,5-benzothiazepine derivatives of the formula: ##STR1## wherein X is hydrogen atom, a halogen atom or a lower alkyl group; R 1 is a lower alkyl group or a lower alkoxy group; R 2 is...
|